SR604
Sponsors
Equilibra Bioscience LLC, Shanghai RAAS Blood Products Co., Ltd.
Conditions
Factor VII DeficiencyHealthy ParticipantsHemophilia AHemophilia BVon Willebrand Disease (VWD)
Phase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingNCT06349473
Start: 2024-05-10End: 2026-09-28Target: 31Updated: 2026-07-02
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
RecruitingNCT07644832
Start: 2024-05-31End: 2026-12-31Target: 76Updated: 2026-06-12
Phase 2
A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease
RecruitingNCT07640893
Start: 2025-11-26End: 2027-12-31Target: 24Updated: 2026-06-11
A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency
Not yet recruitingNCT07711158
Start: 2026-07-01End: 2027-12-01Target: 12Updated: 2026-07-17